FI112082B - Menetelmiä eristetyn CTLA4-reseptorin ja sen johdannaisten, niitä sisältävien tuotteiden ja CTLA-reseptorin tunnistavien vasta-aineiden valmistamiseksi, menetelmissä käyttökelpoisia nukleiinihapposekvenssejä, plasmideja ja isäntäsoluja sekä niiden käyttötapoja - Google Patents

Menetelmiä eristetyn CTLA4-reseptorin ja sen johdannaisten, niitä sisältävien tuotteiden ja CTLA-reseptorin tunnistavien vasta-aineiden valmistamiseksi, menetelmissä käyttökelpoisia nukleiinihapposekvenssejä, plasmideja ja isäntäsoluja sekä niiden käyttötapoja Download PDF

Info

Publication number: FI112082B
Authority: FI; Finland
Prior art keywords: ctla4; amino acid; protein; cells; sequence
Prior art date: 1991-06-27

Application number

FI935795A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI935795A0 (fi

FI935795L (fi

Inventor

Jeffrey A Ledbetter

Peter S Linsley

William Brady

Nitin K Damle

Original Assignee

Squibb Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-27

Filing date

1993-12-22

Publication date

2003-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24907003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112082(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-12-22 Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co

1993-12-22 Publication of FI935795A0 publication Critical patent/FI935795A0/fi

1993-12-22 Publication of FI935795L publication Critical patent/FI935795L/fi

2003-10-31 Application granted granted Critical

2003-10-31 Publication of FI112082B publication Critical patent/FI112082B/fi

Links

101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title claims abstract description 153
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title claims abstract description 138
238000000034 method Methods 0.000 title claims abstract description 53
239000013612 plasmid Substances 0.000 title claims description 16
108020001507 fusion proteins Proteins 0.000 claims abstract description 89
102000037865 fusion proteins Human genes 0.000 claims abstract description 85
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 63
108020003175 receptors Proteins 0.000 claims abstract description 61
102000005962 receptors Human genes 0.000 claims abstract description 58
102000005738 B7 Antigens Human genes 0.000 claims abstract description 44
108010045634 B7 Antigens Proteins 0.000 claims abstract description 44
239000012634 fragment Substances 0.000 claims abstract description 41
230000003993 interaction Effects 0.000 claims abstract description 27
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 23
102000018358 immunoglobulin Human genes 0.000 claims abstract description 23
239000003446 ligand Substances 0.000 claims abstract description 15
210000004027 cell Anatomy 0.000 claims description 147
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 67
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 67
108090000623 proteins and genes Proteins 0.000 claims description 56
150000001413 amino acids Chemical group 0.000 claims description 54
235000018102 proteins Nutrition 0.000 claims description 47
102000004169 proteins and genes Human genes 0.000 claims description 47
241000282414 Homo sapiens Species 0.000 claims description 41
235000001014 amino acid Nutrition 0.000 claims description 40
230000027455 binding Effects 0.000 claims description 36
210000003719 b-lymphocyte Anatomy 0.000 claims description 35
230000004927 fusion Effects 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 26
108020004707 nucleic acids Proteins 0.000 claims description 25
102000039446 nucleic acids Human genes 0.000 claims description 25
239000002299 complementary DNA Substances 0.000 claims description 24
239000013598 vector Substances 0.000 claims description 20
239000000427 antigen Substances 0.000 claims description 17
102000036639 antigens Human genes 0.000 claims description 17
108091007433 antigens Proteins 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 15
102000008203 CTLA-4 Antigen Human genes 0.000 claims description 14
108010021064 CTLA-4 Antigen Proteins 0.000 claims description 14
230000006052 T cell proliferation Effects 0.000 claims description 12
238000000338 in vitro Methods 0.000 claims description 12
108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
235000004279 alanine Nutrition 0.000 claims description 8
235000003704 aspartic acid Nutrition 0.000 claims description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
230000001580 bacterial effect Effects 0.000 claims description 3
210000003527 eukaryotic cell Anatomy 0.000 claims description 3
230000002163 immunogen Effects 0.000 claims description 2
229940024606 amino acid Drugs 0.000 claims 8
239000008194 pharmaceutical composition Substances 0.000 claims 5
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
235000009582 asparagine Nutrition 0.000 claims 2
229960001230 asparagine Drugs 0.000 claims 2
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
241000699800 Cricetinae Species 0.000 claims 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
229940104302 cytosine Drugs 0.000 claims 1
229930182817 methionine Natural products 0.000 claims 1
230000002611 ovarian Effects 0.000 claims 1
230000001235 sensitizing effect Effects 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 abstract description 58
230000028993 immune response Effects 0.000 abstract description 10
230000008614 cellular interaction Effects 0.000 abstract description 9
230000001404 mediated effect Effects 0.000 abstract description 8
108020004414 DNA Proteins 0.000 description 46
238000003752 polymerase chain reaction Methods 0.000 description 28
239000000047 product Substances 0.000 description 25
210000004978 chinese hamster ovary cell Anatomy 0.000 description 22
108010076504 Protein Sorting Signals Proteins 0.000 description 19
210000004698 lymphocyte Anatomy 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
125000000539 amino acid group Chemical group 0.000 description 15
239000002609 medium Substances 0.000 description 15
102000004140 Oncostatin M Human genes 0.000 description 14
108090000630 Oncostatin M Proteins 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
230000000692 anti-sense effect Effects 0.000 description 13
108091034117 Oligonucleotide Proteins 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
239000013615 primer Substances 0.000 description 12
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
102000043321 human CTLA4 Human genes 0.000 description 11
230000000694 effects Effects 0.000 description 10
239000000499 gel Substances 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
230000004044 response Effects 0.000 description 10
238000001890 transfection Methods 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
241001529936 Murinae Species 0.000 description 9
230000003389 potentiating effect Effects 0.000 description 9
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
230000004913 activation Effects 0.000 description 8
238000007792 addition Methods 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000013613 expression plasmid Substances 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
230000001086 cytosolic effect Effects 0.000 description 7
239000000539 dimer Substances 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
241000283707 Capra Species 0.000 description 6
241000699802 Cricetulus griseus Species 0.000 description 6
108010063738 Interleukins Proteins 0.000 description 6
102000015696 Interleukins Human genes 0.000 description 6
102000003979 Mineralocorticoid Receptors Human genes 0.000 description 6
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
238000001114 immunoprecipitation Methods 0.000 description 6
238000012744 immunostaining Methods 0.000 description 6
101150091887 Ctla4 gene Proteins 0.000 description 5
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
108010036949 Cyclosporine Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
206010035226 Plasma cell myeloma Diseases 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
229960001265 ciclosporin Drugs 0.000 description 5
238000010367 cloning Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
229930182912 cyclosporin Natural products 0.000 description 5
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
238000011534 incubation Methods 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
102000010910 CD28 Antigens Human genes 0.000 description 4
108010062433 CD28 Antigens Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
229930105110 Cyclosporin A Natural products 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
241000700605 Viruses Species 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
208000024908 graft versus host disease Diseases 0.000 description 4
230000008611 intercellular interaction Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
210000000612 antigen-presenting cell Anatomy 0.000 description 3
238000000211 autoradiogram Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
239000000710 homodimer Substances 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
-1 isocytochrome C Proteins 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
229960000485 methotrexate Drugs 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000010186 staining Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 2
VHEVVUZDDUCAKU-FXQIFTODSA-N Ala-Met-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O VHEVVUZDDUCAKU-FXQIFTODSA-N 0.000 description 2
PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 2
ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 description 2
QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 2
AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 2
CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 2
241000713842 Avian sarcoma virus Species 0.000 description 2
102000038504 B7-1 Antigen Human genes 0.000 description 2
108010035053 B7-1 Antigen Proteins 0.000 description 2
108010084313 CD58 Antigens Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
TVYMKYUSZSVOAG-ZLUOBGJFSA-N Cys-Ala-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O TVYMKYUSZSVOAG-ZLUOBGJFSA-N 0.000 description 2
ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 2
ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 2
GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 2
NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
102100022339 Integrin alpha-L Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 2
101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
LQUIENKUVKPNIC-ULQDDVLXSA-N Leu-Met-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LQUIENKUVKPNIC-ULQDDVLXSA-N 0.000 description 2
ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 2
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
WWWGMQHQSAUXBU-BQBZGAKWSA-N Met-Gly-Asn Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O WWWGMQHQSAUXBU-BQBZGAKWSA-N 0.000 description 2
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 2
YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 2
SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 2
DYJTXTCEXMCPBF-UFYCRDLUSA-N Pro-Tyr-Phe Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O DYJTXTCEXMCPBF-UFYCRDLUSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 2
WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 2
UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 2
VMSSYINFMOFLJM-KJEVXHAQSA-N Thr-Tyr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCSC)C(=O)O)N)O VMSSYINFMOFLJM-KJEVXHAQSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 2
HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 2
LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
KOPBYUSPXBQIHD-NRPADANISA-N Val-Cys-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KOPBYUSPXBQIHD-NRPADANISA-N 0.000 description 2
OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 2
VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 2
UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 2
ZNGPROMGGGFOAA-JYJNAYRXSA-N Val-Tyr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 ZNGPROMGGGFOAA-JYJNAYRXSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
WCIDIJQCEUODDY-UHFFFAOYSA-N chloro(dimethyl)sulfanium Chemical compound C[S+](C)Cl WCIDIJQCEUODDY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 2
108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 2
108010050848 glycylleucine Proteins 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002998 immunogenetic effect Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
238000001638 lipofection Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
108010085203 methionylmethionine Proteins 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
210000003370 receptor cell Anatomy 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
108010026333 seryl-proline Proteins 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
108010020532 tyrosyl-proline Proteins 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
108020005065 3' Flanking Region Proteins 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
MAEQBGQTDWDSJQ-LSJOCFKGSA-N Ala-Met-His Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MAEQBGQTDWDSJQ-LSJOCFKGSA-N 0.000 description 1
REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
241000713838 Avian myeloblastosis virus Species 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
241001288713 Escherichia coli MC1061 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101100061678 Homo sapiens CTLA4 gene Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
KVNLHIXLLZBAFQ-RWMBFGLXSA-N Lys-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N KVNLHIXLLZBAFQ-RWMBFGLXSA-N 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
PBOUVYGPDSARIS-IUCAKERBSA-N Met-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C PBOUVYGPDSARIS-IUCAKERBSA-N 0.000 description 1
XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
DSXPMZMSJHOKKK-HJOGWXRNSA-N Phe-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DSXPMZMSJHOKKK-HJOGWXRNSA-N 0.000 description 1
APMXLWHMIVWLLR-BZSNNMDCSA-N Phe-Tyr-Ser Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 APMXLWHMIVWLLR-BZSNNMDCSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
QCARZLHECSFOGG-CIUDSAMLSA-N Pro-Glu-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O QCARZLHECSFOGG-CIUDSAMLSA-N 0.000 description 1
UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101150085390 RPM1 gene Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 description 1
UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
KBLYJPQSNGTDIU-LOKLDPHHSA-N Thr-Glu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O KBLYJPQSNGTDIU-LOKLDPHHSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
210000003969 blast cell Anatomy 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
101150062912 cct3 gene Proteins 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000000913 erythropoietic effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000012757 fluorescence staining Methods 0.000 description 1
230000004907 flux Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
201000007294 immune system cancer Diseases 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
230000012177 negative regulation of immune response Effects 0.000 description 1
230000031673 negative regulation of immunoglobulin secretion Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
108010077112 prolyl-proline Proteins 0.000 description 1
108010070643 prolylglutamic acid Proteins 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000013595 supernatant sample Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000003587 threonine derivatives Chemical class 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
108010073969 valyllysine Proteins 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Virology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Physics & Mathematics (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)

FI935795A 1991-06-27 1993-12-22 Menetelmiä eristetyn CTLA4-reseptorin ja sen johdannaisten, niitä sisältävien tuotteiden ja CTLA-reseptorin tunnistavien vasta-aineiden valmistamiseksi, menetelmissä käyttökelpoisia nukleiinihapposekvenssejä, plasmideja ja isäntäsoluja sekä niiden käyttötapoja FI112082B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US72361791A	1991-06-27	1991-06-27
US72361791		1991-06-27
US9205202		1992-06-16
PCT/US1992/005202 WO1993000431A1 (en)	1991-06-27	1992-06-16	Ctl4a receptor, fusion proteins containing it and uses thereof

Publications (3)

Publication Number	Publication Date
FI935795A0 FI935795A0 (fi)	1993-12-22
FI935795L FI935795L (fi)	1993-12-22
FI112082B true FI112082B (fi)	2003-10-31

Family

ID=24907003

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI935795A FI112082B (fi)	1991-06-27	1993-12-22	Menetelmiä eristetyn CTLA4-reseptorin ja sen johdannaisten, niitä sisältävien tuotteiden ja CTLA-reseptorin tunnistavien vasta-aineiden valmistamiseksi, menetelmissä käyttökelpoisia nukleiinihapposekvenssejä, plasmideja ja isäntäsoluja sekä niiden käyttötapoja
FI20022285A FI115057B (fi)	1991-06-27	2002-12-30	Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FI20022285A FI115057B (fi)	1991-06-27	2002-12-30	Eristetty liukoinen CTL4A-proteiini, sitä sisältäviä fuusioproteiineja, sen ligandeja, sen tunnistavia monoklonaalisia vasta-aineita ja käyttötapoja

Country Status (21)

Country	Link
US (1)	US5434131A (no)
EP (1)	EP0606217B2 (no)
JP (6)	JP3722375B2 (no)
KR (1)	KR100238712B1 (no)
AT (1)	ATE170562T1 (no)
AU (1)	AU661854B2 (no)
CA (2)	CA2110518C (no)
DE (2)	DE122007000078I2 (no)
DK (1)	DK0606217T4 (no)
ES (1)	ES2123001T5 (no)
FI (2)	FI112082B (no)
IE (2)	IE922111A1 (no)
IL (4)	IL102294A (no)
LU (1)	LU91375I2 (no)
MX (1)	MX9203605A (no)
NL (1)	NL300303I2 (no)
NO (4)	NO312465B1 (no)
NZ (2)	NZ243286A (no)
PT (1)	PT100637B (no)
WO (1)	WO1993000431A1 (no)
ZA (1)	ZA924782B (no)

Families Citing this family (199)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6685941B1 (en) *	1988-11-23	2004-02-03	The Regents Of The University Of Michigan	Methods of treating autoimmune disease via CTLA-4Ig
CA2003455C (en) *	1988-11-23	2000-02-22	Craig B. Thompson	Immunotherapy involving cd28 stimulation
US6406696B1 (en)	1989-10-27	2002-06-18	Tolerance Therapeutics, Inc.	Methods of stimulating the immune system with anti-CD3 antibodies
EP0839536A1 (en) *	1989-10-27	1998-05-06	Arch Development Corporation	Methods and compositions for promoting immunopotentiation
US5637481A (en) *	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5770197A (en) *	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US6887471B1 (en)	1991-06-27	2005-05-03	Bristol-Myers Squibb Company	Method to inhibit T cell interactions with soluble B7
US6090914A (en) *	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5962406A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US6472510B1 (en) *	1992-02-14	2002-10-29	Bristol-Myers Squibb Company	CD40 receptor ligands
CA2089229C (en) *	1992-02-14	2010-04-13	Alejandro A. Aruffo	Cd40cr receptor and ligands therefor
CA2133075A1 (en) *	1992-04-07	1993-10-14	Craig B. Thompson	CD28 Pathway Immunoregulation
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5397703A (en) *	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5773253A (en) *	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
US6491916B1 (en)	1994-06-01	2002-12-10	Tolerance Therapeutics, Inc.	Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US6106834A (en) *	1993-06-02	2000-08-22	Research Corporation Technologies, Inc.	Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) *	1993-06-02	2000-02-15	Research Corporation Technologies, Inc.	Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
WO1995001994A1 (en) *	1993-07-09	1995-01-19	Synergen, Inc.	Recombinant ctla4 polypeptides and methods for making the same
US6824779B1 (en)	1993-07-26	2004-11-30	Dana-Farber Cancer Institute, Inc.	Methods for inhibiting the interaction of B7-2 with its natural ligand
JPH09500788A (ja)	1993-07-26	1997-01-28	ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド	Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
US6723705B1 (en)	1993-08-19	2004-04-20	Gentics Institute, Inc.	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US20050129670A1 (en) *	1993-07-26	2005-06-16	Genetics Institute, Llc.	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6130316A (en) *	1993-07-26	2000-10-10	Dana Farber Cancer Institute	Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6084067A (en)	1993-07-26	2000-07-04	Dana-Farber Cancer Institute	CTLA4/CD28 ligands and uses therefor
US5861310A (en) *	1993-11-03	1999-01-19	Dana-Farber Cancer Institute	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
AU7526894A (en) *	1993-08-16	1995-03-14	Arch Development Corporation	B7-2: ctla4/cd28 counter receptor
AU7638894A (en) *	1993-09-03	1995-03-22	Miyuki Azuma	B70(b7-2):ctla-4 bonding protein
AU784510B2 (en) *	1994-03-08	2006-04-13	Dana-Farber Cancer Institute, Inc.	Methods for modulating T cell unresponsiveness
EP1025856A3 (en) *	1994-03-08	2002-10-16	Dana-Farber Cancer Institute	Methods for modulating T Cell unresponsiveness
US6719972B1 (en)	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
AU685693B2 (en) *	1994-11-01	1998-01-22	Targeted Genetics Corporation	Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
ES2301164T3 (es)	1994-12-02	2008-06-16	Schering Corporation	Slam, antigeno coestimulador de la superficie de celulas t.
US5576423A (en)	1994-12-02	1996-11-19	Schering Corporation	Antibodies to the slam protein expressed on activated T cells
US5872154A (en) *	1995-02-24	1999-02-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant adenovirus
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6251957B1 (en)	1995-02-24	2001-06-26	Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant virus
US6372208B1 (en)	1999-09-28	2002-04-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant virus
WO1996031229A1 (en) *	1995-04-05	1996-10-10	Beth Israel Hospital Association	Inhibiting rejection of a graft
US7175847B1 (en) *	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) *	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) *	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US5811097A (en) *	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en)	1995-07-25	2000-04-18	The Regents Of The University Of California, Office Of Technology Transfer	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) *	1995-07-25	1999-01-05	The Regents Of The University Of California	Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US7041634B2 (en)	1995-09-27	2006-05-09	Emory University	Method of inhibiting immune system destruction of transplanted viable cells
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6107056A (en) *	1996-02-22	2000-08-22	Oaks; Martin K.	SCTLA-4 gene and product
CA2246352C (en) *	1996-03-20	2011-11-08	Bristol-Myers Squibb Company	Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5786152A (en) *	1996-04-26	1998-07-28	Amgen Inc.	Methods of inhibiting syp binding to a CTLA-4 receptor
EP1007090B1 (en) *	1996-11-08	2009-12-30	Biogen Idec Inc.	Identification of unique binding interactions between certain antibodies and the human b7.1 (cd80) and b7.2 (cd28) co-stimulatory antigens
US20060034844A1 (en) *	1996-12-04	2006-02-16	The Regents Of The University Of California	Stimulation of T cells against self antigens using CTLA-4 blocking agents
US6077833A (en) *	1996-12-31	2000-06-20	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) *	1996-12-31	2004-02-05	Bennett C. Frank	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) *	1996-12-31	2007-06-26	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en)	1996-12-31	2001-11-20	Isis Pharmaceuticals	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
KR19980066046A (ko) *	1997-01-18	1998-10-15	정용훈	고역가의 CTLA4-Ig 융합단백질
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
AU6703198A (en)	1997-03-21	1998-10-20	Brigham And Women's Hospital	Immunotherapeutic ctla-4 binding peptides
SE9701127D0 (sv) *	1997-03-26	1997-03-26	Karolinska Innovations Ab	Antigenic fusionprotein carrying GALal, 3GAL epitopes
WO1998044129A1 (en) *	1997-03-27	1998-10-08	The Council Of The Queensland Institute Of Medical Research	Enhancement of immune response using targeting molecules
EP0975755B2 (en)	1997-04-16	2011-08-03	Millennium Pharmaceuticals, Inc.	Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
AU743939B2 (en)	1997-06-12	2002-02-07	Laboratoires Serono Sa	CD28/CTLA-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same
AU9095498A (en) *	1997-09-19	1999-04-12	Yoshitomi Pharmaceutical Industries, Ltd.	Oligopeptide compounds
US7223729B2 (en) *	1997-11-07	2007-05-29	Trillium Therapeutics Inc.	Methods of treating allergy by administering a CD200 protein
CA2308765C (en)	1997-11-07	2010-10-12	Transplantation Technologies Inc.	The use of an ox-2 protein or nucleic acid in immunomodulation
US6955811B2 (en) *	1997-11-07	2005-10-18	Trillium Therapeutics Inc.	Methods of inhibiting immune response suppression by administering antibodies to OX-2
AUPP221098A0 (en) *	1998-03-06	1998-04-02	Diatech Pty Ltd	V-like domain binding molecules
ES2246567T3 (es) *	1998-04-15	2006-02-16	Brigham & Womens Hospital	Composiciones para receptores inhibidores de celulas t y usos de las mismas.
US7279168B2 (en)	1998-05-01	2007-10-09	Texas A & M University System	Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
US7078512B2 (en)	1998-05-01	2006-07-18	Schering-Plough Animal Health Corporation	Nucleic acid encoding feline CD86
US20050031611A1 (en) *	1998-05-08	2005-02-10	Beth Israel Deaconess Medical Center	Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
US6682741B1 (en)	1998-06-10	2004-01-27	The United States Of America As Represented By The Department Of Health And Human Services	β2 microglobulin fusion proteins and high affinity variants
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
EP1088084B1 (en) *	1998-06-15	2006-09-13	GTC Biotherapeutics, Inc.	Erythropoietin analog-human serum albumin fusion protein
US6593133B1 (en)	1998-07-06	2003-07-15	Nsgene A/S	Neurotrophic factors
WO2000016801A1 (en)	1998-09-21	2000-03-30	Genetics Institute, Inc.	Methods of downmodulating the immune response to therapeutic proteins
US6521419B1 (en)	1998-09-22	2003-02-18	Kanakaraju Koduri	Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en)	1998-09-22	2004-10-05	Bristol-Myers Squibb Company	Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
ES2706547T3 (es)	1998-12-23	2019-03-29	Pfizer	Anticuerpos monoclonales humanos para CTLA-4
US7011833B1 (en)	1999-05-06	2006-03-14	Genetics Institute, Inc.	Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
WO2001008700A1 (en) *	1999-07-28	2001-02-08	Genetics Institute, Inc.	Preventing immune-mediated abortion by inhibiting costimulation
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
PT1212422E (pt)	1999-08-24	2007-04-30	Medarex Inc	Anticorpos contra citla-4 humana e suas utilizações
ES2391760T3 (es) *	2000-01-03	2012-11-29	The Trustees Of The University Of Pennsylvania	Proteínas quiméricas novedosas y métodos para usar las mismas
US7541184B2 (en)	2000-02-24	2009-06-02	Invitrogen Corporation	Activation and expansion of cells
US7572631B2 (en) *	2000-02-24	2009-08-11	Invitrogen Corporation	Activation and expansion of T cells
TWI319405B (en) *	2000-05-26	2010-01-11	Bristol Myers Squibb Co	Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
CA2411962A1 (en) *	2000-06-09	2001-12-20	Bristol-Myers Squibb Company	Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
US20050048614A1 (en) *	2000-06-13	2005-03-03	Children's Medical Center Corporation	Biosynthetic oncolytic molecules and uses therefor
US20040034193A1 (en) *	2001-06-13	2004-02-19	Samy Ashkar	Biosynthetic oncolytic molecules and uses therefor
JP2004517806A (ja)	2000-07-03	2004-06-17	ブリストル−マイヤーズ　スクイブ　カンパニー	可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6875904B2 (en) *	2000-09-20	2005-04-05	The Ohio State University Research Foundation	Animal model for identifying agents that inhibit or enhance CTLA4 signaling
US7014998B2 (en) *	2000-09-30	2006-03-21	Yale University	Screening immunomodulatory agents by CTLA-4 upregulation
US20040198661A1 (en) *	2000-12-08	2004-10-07	Bowdish Katherine S.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) *	2000-12-08	2016-02-02	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) *	2000-12-08	2006-03-16	Bowdish Katherine S	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) *	2000-12-08	2002-08-01	Alexion Pharmaceuticals, Inc.	Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) *	2000-12-08	2008-08-05	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
EP1368059A1 (en) *	2001-01-26	2003-12-10	Emory University	Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
TWI329129B (en) *	2001-02-08	2010-08-21	Wyeth Corp	Modified and stabilized gdf propeptides and uses thereof
EP1395279B1 (en)	2001-03-28	2011-10-05	Biogen Idec MA Inc.	Use of neublastin polypeptides for treating neuropathic pain
US20040058445A1 (en) *	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
DE60225914T2 (de)	2001-05-23	2009-07-23	Bristol-Myers Squibb Co.	Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
KR100453877B1 (ko)	2001-07-26	2004-10-20	메덱스젠 주식회사	연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030086940A1 (en) *	2001-08-10	2003-05-08	Cristina Costa	Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
US20040116675A1 (en) *	2001-12-14	2004-06-17	Tso J. Jun	Silenced anti-cd28 antibodies and use thereof
ES2337989T3 (es) *	2001-12-18	2010-05-03	Endocube Sas	Nuevas proteinas asociadas a la muerte de la familia thap y rutas par4 relacionadas implicadas en el control de la apoptosis.
US7858297B2 (en) *	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
US6578724B1 (en) *	2001-12-29	2003-06-17	United States Can Company	Connector for use in packaging aerosol containers
EP1585817B1 (en)	2002-02-20	2009-09-02	The General Hospital Corporation	Conjugates comprising a biodegradable polymer and uses therefor
US20030219436A1 (en) *	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
CA2481207C (en) *	2002-04-12	2015-06-30	Medarex, Inc.	Methods of treatment using ctla-4 antibodies
CA2485098A1 (en) *	2002-05-02	2003-11-13	University Of Connecticut Health Center	Use of heat shock proteins to enhance efficacy of antibody therapeutics
WO2004034995A2 (en) *	2002-10-15	2004-04-29	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Methods and reagents for inducing immunity
DE60335024D1 (de) *	2002-12-23	2010-12-30	Bristol Myers Squibb Co	Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
EP1575998A4 (en) *	2002-12-23	2007-07-25	Bristol Myers Squibb Co	PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
DK1594436T3 (da)	2003-01-31	2010-12-13	Biogen Idec Inc	Polymerkonjugater af muteret neublastin
GB0303663D0 (en) *	2003-02-18	2003-03-19	Lorantis Ltd	Assays and medical treatments
US7897582B2 (en) *	2003-05-23	2011-03-01	Isis Pharmaceuticals, Inc.	Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) *	2003-05-23	2011-06-14	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of the expression of B7 protein
US6971600B2 (en) *	2003-06-30	2005-12-06	Heligear Engineering (H.K.) Co., Ltd.	Oscillation mechanism for fishing reel
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
EP1670499A4 (en) *	2003-08-04	2009-07-22	Bristol Myers Squibb Co	METHODS OF TREATING A CARDIOVASCULAR DISEASE USING A SOLUBLE CTLA4 MOLECULE
CA2543484C (en) *	2003-10-27	2014-02-04	Amgen Inc.	Modulation of immune response to an immunogen with ctla-4 and tnfbp
US20080152655A1 (en) *	2004-09-08	2008-06-26	The Ohio State University Research Foundation	Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
EP1793858A4 (en) *	2004-09-08	2008-12-10	Univ Ohio State Res Found	HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
GB0421465D0 (en) *	2004-09-27	2004-10-27	Chiron Srl	Group A streptococcus protein
LT1868635T (lt) *	2005-04-06	2017-07-10	Bristol-Myers Squibb Company	Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
SG163615A1 (en)	2005-07-11	2010-08-30	Macrogenics Inc	Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2616395C (en)	2005-07-25	2016-10-04	Trubion Pharmaceuticals	B-cell reduction using cd37-specific and cd20-specific binding molecules
JP4899083B2 (ja) *	2005-08-29	2012-03-21	Ｓｍｃ株式会社	減速比自動切換装置
US8501704B2 (en)	2005-11-08	2013-08-06	Sarepta Therapeutics, Inc.	Immunosuppression compound and treatment method
EP1954836B1 (en) *	2005-11-08	2014-01-08	Sarepta Therapeutics, Inc.	Immunosuppression compound and treatment method
AU2013202533B2 (en) *	2005-11-08	2015-11-12	Sarepta Therapeutics, Inc.	Immunosuppression Compound and Treatment Method
US8110194B2 (en)	2005-12-07	2012-02-07	Medarex, Inc.	CTLA-4 antibody dosage escalation regimens
BRPI0622251A2 (pt)	2005-12-20	2011-07-19	Bristol-Myers Squibb Company	método para obtenção de uma composição compreendendo uma população isolada de moléculas de ctla4-ig de um meio de cultura lìquido e para isolamento de uma composição compreendendo moléculas de ctla4-ig e composição
JP5404052B2 (ja)	2006-01-12	2014-01-29	アレクシオンファーマシューティカルズ，インコーポレイテッド	Ｏｘ−２／ｃｄ２００への抗体およびその使用
CA2646329C (en)	2006-03-20	2018-07-03	The Regents Of The University Of California	Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US7528111B2 (en) *	2006-05-12	2009-05-05	Bristol-Myers Squibb Company	Method of vaccinating subjects receiving immune modulating therapy
EP3805269A1 (en)	2006-06-12	2021-04-14	Aptevo Research and Development LLC	Single-chain multivalent binding proteins with effector function
EP2037961B1 (en)	2006-06-14	2015-11-11	MacroGenics, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
US8986684B2 (en) *	2007-07-25	2015-03-24	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating autoimmune disease
CA2698343C (en)	2007-09-04	2018-06-12	The Regents Of The University Of California	High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
PL2222697T3 (pl)	2007-11-01	2013-05-31	Astellas Pharma Inc	Immunosupresyjne polipeptydy i kwasy nukleinowe
KR20110013391A (ko)	2008-04-11	2011-02-09	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
US7915222B2 (en) *	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
LT2344540T (lt)	2008-10-02	2018-03-26	Aptevo Research And Development Llc	Prie daugybinių taikinių prisirišantys cd86 antagonistiniai baltymai
AU2009313877A1 (en) *	2008-11-13	2011-06-30	Emergent Product Development Seattle, Llc	CD37 immunotherapeutic combination therapies and uses thereof
ES2666152T3 (es) *	2009-08-13	2018-05-03	The Johns Hopkins University	Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
US9540426B2 (en)	2009-10-06	2017-01-10	Bristol-Myers Squibb Company	Mammalian cell culture processes for protein production
AU2010308030B2 (en)	2009-10-12	2014-05-29	Pfizer Inc.	Cancer treatment
US8642557B2 (en)	2010-03-12	2014-02-04	Abbvie Biotherapeutics Inc.	CTLA4 proteins and their uses
EP4450523A3 (en)	2010-04-02	2025-03-12	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2012042480A1 (en)	2010-09-28	2012-04-05	Kahr Medical Ltd.	Compositions and methods for treatment of hematological malignancies
WO2013010537A1 (en)	2011-07-20	2013-01-24	Aarhus Universitet	Method of treating morphea
WO2013148049A1 (en)	2012-03-29	2013-10-03	The General Hospital Corporation	Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
WO2013169971A1 (en)	2012-05-10	2013-11-14	Bristol-Myers Squibb Company	Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
AU2013260172B2 (en)	2012-05-11	2017-11-23	Medimmune Limited	CTLA-4 variants
US8735359B2 (en)	2012-05-24	2014-05-27	Orban Biotech Llc	Combinations of modalities for the treatment of diabetes
CN113138279A (zh)	2012-06-27	2021-07-20	法姆制药有限责任公司	融合蛋白组合物的应用
US20140112958A1 (en)	2012-10-24	2014-04-24	Mwm Biomodels Gmbh	Pancreatic islets of transgenic LEA29Y animals for treating diabetes
US9944689B2 (en)	2013-03-07	2018-04-17	The General Hospital Corporation	Human CTLA4 mutants and use thereof
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
EP2883883A1 (en)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutic targets and agents useful in treating ischemia reperfusion injury
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB2523399B (en)	2014-02-25	2019-03-13	Orban Tihamer	A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
ME03558B (me)	2014-03-14	2020-07-20	Novartis Ag	Molekuli anti-lag-3 antiтela i njihove upotrebe
RU2718914C2 (ru)	2014-09-13	2020-04-15	Новартис Аг	Сочетанные способы лечения с использованием ингибиторов alk
LT3240801T (lt)	2014-12-31	2021-02-25	Checkmate Pharmaceuticals, Inc.	Kombinuota navikų imunoterapija
PL3283508T3 (pl)	2015-04-17	2021-10-11	Alpine Immune Sciences, Inc.	Białka immunomodulacyjne o dostrajalnym powinowactwie
JP7002446B2 (ja)	2015-09-21	2022-03-04	アプティーボリサーチアンドデベロップメントエルエルシー	Ｃｄ３結合ポリペプチド
EP3192805A1 (en)	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibitors of t cell activation or stimulation and uses thereof
CN116440257A (zh)	2017-02-28	2023-07-18	百时美施贵宝公司	具有增强的adcc的抗ctla-4抗体增强对疫苗的免疫应答的用途
CA3055769A1 (en)	2017-04-03	2018-10-11	Oncologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
US11761963B2 (en)	2017-09-27	2023-09-19	Alexion Pharmaceuticals, Inc.	Biomarker signature for predicting tumor response to anti-CD200 therapy
CN111801347A (zh)	2017-10-10	2020-10-20	高山免疫科学股份有限公司	Ctla-4变体免疫调节蛋白和其用途
EP3752194A4 (en)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
JP7511478B2 (ja)	2018-04-09	2024-07-05	チェックメイトファーマシューティカルズ	ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
EP3617230A1 (en)	2018-09-03	2020-03-04	BioInvent International AB	Novel antibodies and nucleotide sequences, and uses thereof
SG11202104337PA (en)	2018-11-26	2021-05-28	Massachusetts Inst Technology	Compositions and methods for immune tolerance
JP2023503442A (ja)	2019-11-21	2023-01-30	ブリストル－マイヤーズスクイブカンパニー	無標識ｎ－グリカン定量化方法
JP2024507220A (ja)	2021-02-19	2024-02-16	セリピオン，インコーポレイテッド	パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
GB202115803D0 (en)	2021-11-03	2021-12-15	Ducentis Biotherapeutics Ltd	Novel proteins
EP4519297A1 (en)	2022-05-06	2025-03-12	Ducentis Biotherapeutics Limited	Novel cd200 fusion proteins
WO2023214388A1 (en)	2022-05-06	2023-11-09	Ducentis Biotherapeutics Limited	Novel cd200 fusion proteins
CN114686427B (zh) *	2022-05-23	2022-07-29	中国人民解放军总医院第一医学中心	一种脾脏调节型b淋巴细胞及其制备方法与应用
GB202306711D0 (en)	2023-05-05	2023-06-21	Ducentis Biotherapeutics Ltd	Novel proteins
WO2024259220A1 (en)	2023-06-15	2024-12-19	Theripion, Inc.	Pon3 and evolved pon1 fusion polypeptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en) *	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4683195A (en) *	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences

1992
- 1992-06-16 CA CA002110518A patent/CA2110518C/en not_active Expired - Lifetime
- 1992-06-16 CA CA002580812A patent/CA2580812A1/en not_active Abandoned
- 1992-06-16 EP EP92914009A patent/EP0606217B2/en not_active Expired - Lifetime
- 1992-06-16 WO PCT/US1992/005202 patent/WO1993000431A1/en active IP Right Grant
- 1992-06-16 AT AT92914009T patent/ATE170562T1/de active
- 1992-06-16 AU AU22400/92A patent/AU661854B2/en not_active Expired
- 1992-06-16 DE DE122007000078C patent/DE122007000078I2/de active Active
- 1992-06-16 JP JP50156993A patent/JP3722375B2/ja not_active Expired - Lifetime
- 1992-06-16 KR KR1019930703876A patent/KR100238712B1/ko not_active IP Right Cessation
- 1992-06-16 ES ES92914009T patent/ES2123001T5/es not_active Expired - Lifetime
- 1992-06-16 DK DK92914009T patent/DK0606217T4/da active
- 1992-06-16 DE DE69226871T patent/DE69226871T3/de not_active Expired - Lifetime
- 1992-06-24 IL IL10229492A patent/IL102294A/en not_active IP Right Cessation
- 1992-06-24 NZ NZ243286A patent/NZ243286A/en not_active IP Right Cessation
- 1992-06-24 NZ NZ264712A patent/NZ264712A/en not_active IP Right Cessation
- 1992-06-24 IL IL15936492A patent/IL159364A/xx not_active IP Right Cessation
- 1992-06-26 PT PT100637A patent/PT100637B/pt not_active IP Right Cessation
- 1992-06-26 MX MX9203605A patent/MX9203605A/es active IP Right Grant
- 1992-06-26 ZA ZA924782A patent/ZA924782B/xx unknown
- 1992-07-01 IE IE211192A patent/IE922111A1/en not_active IP Right Cessation
- 1992-07-01 IE IE20010097A patent/IE20010097A1/en not_active IP Right Cessation
1993
- 1993-05-26 US US08/067,684 patent/US5434131A/en not_active Expired - Lifetime
- 1993-12-22 FI FI935795A patent/FI112082B/fi not_active IP Right Cessation
- 1993-12-23 NO NO19934801A patent/NO312465B1/no not_active IP Right Cessation
2001
- 2001-05-07 JP JP2001136664A patent/JP2002003399A/ja not_active Withdrawn
- 2001-05-07 JP JP2001136657A patent/JP4159266B2/ja not_active Expired - Lifetime
2002
- 2002-01-30 NO NO20020491A patent/NO318806B1/no not_active IP Right Cessation
- 2002-04-11 JP JP2002109829A patent/JP2003012546A/ja not_active Withdrawn
- 2002-07-22 JP JP2002213195A patent/JP2003096097A/ja not_active Withdrawn
- 2002-10-01 JP JP2002289290A patent/JP2003174872A/ja active Pending
- 2002-12-30 FI FI20022285A patent/FI115057B/fi not_active IP Right Cessation
2003
- 2003-12-15 IL IL15936403A patent/IL159364A0/xx unknown
2004
- 2004-06-10 IL IL16243004A patent/IL162430A0/xx unknown
2007
- 2007-11-02 NL NL300303C patent/NL300303I2/nl unknown
- 2007-11-07 LU LU91375C patent/LU91375I2/fr unknown
- 2007-11-14 NO NO2007013C patent/NO2007013I2/no unknown
2012
- 2012-01-09 NO NO2012001C patent/NO2012001I2/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69226871D1 (de)	1998-10-08
IL102294A (en)	2004-09-27
NL300303I1 (nl)	2008-01-02
ATE170562T1 (de)	1998-09-15
JP2003012546A (ja)	2003-01-15
EP0606217B2 (en)	2008-12-03
NO318806B1 (no)	2005-05-09
NO2012001I1 (no)	2012-01-09
FI935795A0 (fi)	1993-12-22
NZ243286A (en)	1996-03-26
NO20020491D0 (no)	2002-01-30
DE122007000078I1 (de)	2008-02-14
IL102294A0 (en)	1993-01-14
JP2002017349A (ja)	2002-01-22
EP0606217A1 (en)	1994-07-20
AU2240092A (en)	1993-01-25
AU661854B2 (en)	1995-08-10
IL159364A0 (en)	2004-06-01
NO934801D0 (no)	1993-12-23
NO934801L (no)	1994-02-21
US5434131A (en)	1995-07-18
JP2003174872A (ja)	2003-06-24
DK0606217T3 (da)	1998-11-09
IE20010097A1 (en)	2002-03-20
DE122007000078I2 (de)	2011-01-13
CA2580812A1 (en)	1993-01-07
JP3722375B2 (ja)	2005-11-30
NO2007013I2 (no)	2011-02-21
FI935795L (fi)	1993-12-22
PT100637A (pt)	1994-05-31
JPH06508989A (ja)	1994-10-13
EP0606217B1 (en)	1998-09-02
PT100637B (pt)	1999-06-30
CA2110518A1 (en)	1993-01-07
IE922111A1 (en)	1992-12-30
IL159364A (en)	2005-08-31
WO1993000431A1 (en)	1993-01-07
KR940701445A (ko)	1994-05-28
LU91375I2 (fr)	2008-01-07
NL300303I2 (nl)	2008-01-02
ES2123001T3 (es)	1999-01-01
FI115057B (fi)	2005-02-28
DK0606217T4 (da)	2009-03-30
ZA924782B (en)	1993-12-27
NO2007013I1 (no)	2007-11-26
DE69226871T2 (de)	1999-05-12
JP4159266B2 (ja)	2008-10-01
NO312465B1 (no)	2002-05-13
CA2110518C (en)	2007-05-22
MX9203605A (es)	1993-11-01
NZ264712A (en)	1996-03-26
KR100238712B1 (ko)	2000-01-15
IL162430A0 (en)	2005-11-20
FI20022285L (fi)	2002-12-30
JP2002003399A (ja)	2002-01-09
NO2012001I2 (no)	2016-02-29
JP2003096097A (ja)	2003-04-03
DE69226871T3 (de)	2009-09-24
NO20020491L (no)	1994-02-21
ES2123001T5 (es)	2009-04-16

Publication	Publication Date	Title
FI112082B (fi)	2003-10-31	Menetelmiä eristetyn CTLA4-reseptorin ja sen johdannaisten, niitä sisältävien tuotteiden ja CTLA-reseptorin tunnistavien vasta-aineiden valmistamiseksi, menetelmissä käyttökelpoisia nukleiinihapposekvenssejä, plasmideja ja isäntäsoluja sekä niiden käyttötapoja
CA2113744C (en)	2008-12-30	Methods for regulating the immune response using ctla4-binding molecules and il4-binding molecules
FI120041B (fi)	2009-06-15	Liukoisia CTLA4-molekyyleja ja niiden käyttöjä
US5977318A (en)	1999-11-02	CTLA4 receptor and uses thereof
US5844095A (en)	1998-12-01	CTLA4 Ig fusion proteins
US7572772B2 (en)	2009-08-11	Soluble CTLA4 mutant molecules

Legal Events

Date	Code	Title	Description
2007-11-13	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: L20070034
2011-08-29	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: SPCG Extension date: 20171216
2012-08-10	MA	Patent expired

Date

Code

Title

Description

2007-11-13

SPCF

Supplementary protection certificate application filed

Spc suppl protection certif: L20070034

2011-08-29

SPCG

Supplementary protection certificate granted

Spc suppl protection certif: SPCG

Extension date: 20171216

2012-08-10

Patent expired